Pfizer, however, said that it has not experienced production issues. In a statement Thursday, the company said it shipped all 2.9 million doses of the vaccine the U.S. had allotted so far, and has millions more doses in warehouses ready to send. Those include doses being held for a required second shot, as well as a new batch set for delivery over the coming week.
Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui is serving as chief adviser on the American effort to find a vaccine for the coronavirus disease (COVID-19) pandemic.
PHOTO BY KEVIN LAMARQUE / REUTERS
“Pfizer is not having any production issues with our Covid-19 vaccine, and no shipments containing the vaccine are on hold or delayed,” the company said, making clear the company had many more doses available right now than were being distributed.
“We have millions more doses sitting in our warehouse but, as of now, we have not received any shipment instructions for additional doses,” the statement read.
The clashing accounts came as Pfizer and the Trump administration negotiate additional vaccine doses for the United States.
In recent days, there has been growing frustration in the Trump administration with the company. A senior administration official who spoke on condition of anonymity to discuss details of the vaccine program said Pfizer is negotiating in public despite having delivery problems and not meeting the initial volumes that the U.S. had expected.
No comments:
Post a Comment